These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose https://dawudnudu655946.dreamyblogs.com/39476603/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide